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Editorial 
Should long-acting &agonists be considered an 
alternative first choice option for the treatment of 
stable COPD? 
M. CAZZOLA AND M. G. MATERA 
“S. Maugen” Foundation, Institute of Care and Research, Medical Centre of Rehabilitation, 
Clinical Pharmacology Unit and Respiratory Pharmacology Center, Veruno, (NO), Italy 
Current opinion is that &adrenoceptor agonists are more 
active than anticholinergic drugs in the symptomatic treat- 
ment of bronchial asthma, whereas anticholinergic agents 
are equally effective and/or more efficacious than 
&adrenoceptor agonists in chronic obstructive pulmonary 
disease (COPD) or emphysema. The acceptance of anti- 
cholinergic drugs for the reduction of dyspnoea in stable 
COPD outpatients, as opposed to &agonists, is mainly due 
to its slightly longer duration of action and very low 
incidence of adverse effects when used at the recommended 
dosages (1). In effect, 36 out of 38 published studies which 
compared anticholinergic agents and Pa-adrenoceptor 
agonists on various spirometric parameters found anti- 
cholinergic agents to be at least equal, and generally 
superior, to &-adrenoceptor agonists (2). Consequently, the 
recent guidelines from the American Thoracic Society (3) 
suggest the inhaled administration of an anticholinergic 
agent as first-line therapy in stable COPD. 
The mechanisms by which anticholinergics may have a 
greater effect on airway function in COPD are uncertain as, 
if cholinergic tone were the only reversible component, it 
might be predicted that &agonists would be equally effec- 
tive in inhibiting cholinergic tone. In any case, in normal 
airways vagal bronchomotor tone has little effect on airway 
calibre but when the airways are narrowed to the same 
degree of tone in COPD this has a marked effect on 
airway resistance (which is proportional to the fourth 
power of the radius). Consequently, reversing this tone 
by anticholinergic drugs will have a significant beneficial 
effect (4). 
Da-agonists remain first-line therapy only for the acute 
relief of COPD symptoms because of their rapid onset of 
action (1). However, the introduction of long-acting 
&adrenoceptor agonists (e.g. salmeterol and formoterol) 
gives physicians additional therapeutic options for 
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stable COPD. Both salmeterol and formoterol induce 
an improvement in airflow limitation after long-term 
therapy ($6). 
Unfortunately, only a few studies have compared the 
efficacy of long-acting &agonists with anticholinergic 
agents. We (7) have recently proved that the onset of 
bronchodilation after 4Opg ipratropium bromide is slower 
than that after 200 pg salbutamol, but ipratropium bromide 
produces a longer-lasting bronchodilation than salbutamol. 
However, 50,~~g salmeterol is as effective as ipratropium 
bromide in terms of the degree of bronchodilation and has 
a longer duration of action than ipratropium bromide. A 
later American study (8) has confirmed our finding and 
showed that a single administration of 42pg salmeterol 
produced a greater improvement in pulmonary function 
than two administrations of 36,~~g ipratropium in patients 
who demonstrated reversibility to ipratropium. We must 
highlight that the clinically recommended dose of ipratro- 
pium used in both studies might be considered too low as 
forced expiratory volume in 1 set (FEV,) reached a plateau 
only after administration of a cumulative dose of 280 ,ug (14 
puffs) in patients with COPD (9). It is unlikely that a 
patient suffering from COPD would inhale 14 cumulative 
puffs in rapid succession 3-4 times daily. In any case, we 
(10) have also shown that four puffs (400 pg) of oxitropium 
bromide, another anticholinergic drug which produces a 
similar degree of bronchodilation to that obtained with 
ipratropium bromide but with a longer-lasting effect (II), 
would approximate two puffs of salmeterol(50 pug) in terms 
of mean peak response, but that salmeterol has a longer 
duration of action than oxitropium. We emphasize that 
200 pg oxitropium and 50 ,ug salmeterol are dosages recom- 
mended for regular therapy, but our study demonstrated 
that 200,~~g oxitropium bromide was not sufficient to 
achieve optimal bronchodilation. 
Recently, salmeterol (42 pg bid) has been compared with 
ipratropium (36pg qid) over 1Zweek periods in a double- 
blind, placebo-controlled, cross-over study involving 8 13 
patients with mild to moderate COPD. During salmeterol 
treatment, subjects did statistically better in terms of all 
the measured parameters (12) and, equally importantly, 
salmeterol was as safe as ipratropium (13). 
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As &agonists and anticholinergic agents are distinct 
classes of drugs with different mechanisms of action, an 
additive effect may be expected (4). For these reasons the 
American Thoracic Society (3) suggests increasing the 
dosage of ipratropium to as high as six puffs every 6-8 h 
and then adding up to four puffs of a short-acting 
&agonist four times daily as needed or as scheduled. 
However, a number of clinical studies have shown a 
benefit of combining low doses of a P-agonist with an 
anticholinergic agent. For instance, in 534 patients suffer- 
ing from COPD the combination of ipratropium and 
salbutamol was more effective that either of the two drugs 
alone after 12 weeks of treatment (14). We have docu- 
mented in 12 patients with stable COPD that 4Opg 
ipratropium does not produce any further bronchodilation 
than that achieved with 5Opg salmeterol alone, although 
the onset of action after the combination of the two drugs 
may be faster than after salmeterol alone (15). It is 
conceivable that the subjects studied in this specific clini- 
cal situation were at the top of their bronchodilation 
response curve after inhalation of salmeterol. In any case, 
the results of this study apparently refute the assertion 
that airways obstruction secondary to increased vagal 
tone is the only dominant reversible element in patients 
suffering from COPD. Nonetheless, van Noord et al. (16) 
have recently demonstrated that a 12-week treatment with 
50,ug salmeterol bid plus 40,ug ipratropium bromide qid 
was more effective than 50,ug salmeterol bid in improving 
FEV, and specific airway conductance (SGAW) in 144 
patients with moderate to severe COPD, although the 
patients did not experience any additional effect in symp- 
tom control. In any case, the use of salbutamol as rescue 
medication in order to cause rapid relief of bronchospasm 
in patients suffering from partially reversible COPD is 
always possible after single conventional inhaled dose of a 
long-acting &adrenoceptor agonist (17). 
All these recent findings with long-acting B,-agonists 
raise the question if it is still correct to consider an 
anticholinergic drug as the bronchodilator therapy of first 
choice in the treatment of stable COPD. The late British 
Thoracic Society guidelines (18) for the management of 
COPD suggest starting with short-acting &agonists used 
as required and adding or substituting an anticholinergic 
when &agonists do not control symptoms or if regular 
maintenance therapy is desired. Moreover, these guidelines 
recommend limiting the use of long-acting &-agonists to 
patients with a demonstrable response to short-acting 
P,-agonists. This limitation is not correct. In fact, we (19) 
have demonstrated that patients with COPD who do not 
manifest early reversibility to salbutamol can still benefit 
from salmeterol. Therefore, treatments with long-acting 
&agonists must always be tried. 
For all considerations, we believe that long-acting 
&-agonists should be considered an alternative first-choice 
option to the algorithm supplied by Ferguson and 
Cherniack (20) (Fig. 1). However, since those patients 
suffering from COPD with pre-existing cardiac arrhythmias 
being treated with long-acting &agonists could be at 
special risk of developing new arrhythmias or of aggravat- 
ing pre-existing ones (21), the use of anticholinergic drugs is 
preferable in COPD patients suffering from pre-existing 
cardiac arrhythmias and hypoxaemia. 
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